REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on January 31, 2024. One individual was hired by Adicet in January 2024 and granted new hire non-qualified stock options to purchase 7,000 shares of Adicet’s common stock with an exercise price of $2.99 per share, the closing price of Adicet ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the closing of its previously announced underwritten public offering of 32,379,667 shares of its common stock, which includes 5,325,000 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock, and, ...

ACET公司表现 - ACET 是医疗行业中表现出色的公司之一[1] - ACET 目前的 Zacks Rank 为 2 (Buy)，显示其盈利前景较好[3] - ACET 今年迄今为止的股价上涨了约27%，表现优于医疗行业平均下跌1.5%的情况[5] - ACET 属于医疗 - 生物医学和遗传学行业，该行业今年迄今下跌了约13.9%，而ACET的表现优于该行业[8] ADMA公司表现 - Adma Biologics (ADMA) 也是医疗行业中表现较好的股票之一，今年迄今回报率为11.7%[6] - ADMA 过去三个月的一致 EPS 预期增长了91.4%，目前也拥有 Zacks Rank 2 (Buy)[7] 投资建议 - 投资者应密切关注 ACET 和 ADMA，因为它们正在努力维持良好的表现[9]

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock. The shares of common stock are being sold at a public off ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The purchase price of each pre-funded warrant will equal the price per share ...

公司介绍 - Adicet Bio是一家临床阶段公司，开发具有新型作用机制的“现货”γδT细胞疗法，用于治疗癌症和自身免疫性疾病[1] - 公司的主力产品候选药ADI-001是一种靶向CD20的γδ CAR T细胞疗法，目前正在进行一项I期研究，用于治疗复发或难治的侵袭性B细胞非霍奇金淋巴瘤[2] 股价表现 - Adicet股价在过去一个月飙升了130.4%，远高于行业的4.9%上涨，这一股价大幅上涨是由公司本月早些时候提供的企业更新引发的，讨论了2024年的战略重点，并重申了公司在2024年的几个重要里程碑[3]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adicet Bio, Inc. (ACET) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adicet Bio, Inc. is a member of the Medical sector. This group includes 1077 ind ...

公司介绍 - Adicet Bio, Inc.（纳斯达克股票代码：ACET）是一家临床阶段的生物技术公司，致力于发现和开发用于癌症和自身免疫疾病的异基因伽马-δ T细胞疗法[1] 产品介绍 - ADI-001是一种调查性的异基因伽马-δ CAR T细胞疗法，针对CD20，用于治疗复发性或难治性B细胞非霍奇金淋巴瘤（NHL）和自身免疫疾病[2] 临床试验 - ADI-001已获得美国FDA在狼疮性肾炎方面的IND批准，计划在2024年第二季度启动ADI-001治疗狼疮性肾炎的临床试验[3]

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under “Prese ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on December 29, 2023. One individual was hired by Adicet in December 2023 and granted new hire non-qualified stock options to purchase 84,000 shares of Adicet’s common stock with an exercise price of $1.89 per share, the closing price of Adicet’s common stock as re ...